Buecklein et al., 2018 - Google Patents
Flow cytometric assessment of minimal residual disease in AML: National harmonization in the HARMONIZE initiativeBuecklein et al., 2018
- Document ID
- 17979812083391131316
- Author
- Buecklein V
- Schnorfeil F
- Koehnke T
- Spiekermann K
- Krause S
- Oelschlägel U
- Völkl S
- Rieger M
- Berg T
- Hoffmann J
- Brendel C
- Hofmeister-Mielke N
- Kriegsmann K
- Thiede C
- von Bonin M
- Subklewe M
- Publication year
- Publication venue
- Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
External Links
Snippet
Methods: In a retrospective analysis of pilot data from one center (Munich), bone marrow samples from AML patients after intensive induction chemotherapy were assessed by multicolor flow cytometry at aplasia and post induction. The Kaplan-Meier estimator and log …
- 206010000880 Acute myeloid leukaemia 0 title abstract description 32
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11932696B2 (en) | Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells | |
CN106068276B (en) | Chimeric Antigen Receptor (CAR) with antigen binding domain to T cell receptor beta constant region | |
US20220152176A1 (en) | Cancer biomarkers for durable clinical benefit | |
KR20190026740A (en) | Treatment of B-cell malignancies using adoptive cell therapy | |
Zeng et al. | Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia | |
JP2021503952A (en) | CAR-T cells targeting IL-1RAP and their use | |
JP2021503952A5 (en) | ||
Hanvesakul et al. | KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation | |
Zhang et al. | Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice | |
Somasundaram et al. | Systemic immune dysfunction in cancer patients driven by IL6 induction of LAG3 in peripheral CD8+ T cells | |
Buecklein et al. | Flow cytometric assessment of minimal residual disease in AML: National harmonization in the HARMONIZE initiative | |
Won et al. | A new triggering receptor expressed on myeloid cells (TREM) family member, TLT-6, is involved in activation and proliferation of macrophages | |
CA3218590A1 (en) | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use | |
Trefny | Resistance Mechanisms in Cancer Immunotherapy | |
Dwivedi | Effect of claudin-6 and claudin-9 on NK cell cytotoxic activity against AGS cell line= Efecto de claudina-6 y claudina-9 sobre la actividad citotóxica de células NK contra la línea celular AGS | |
Parisi | Immune response against Wilms Tumor: characterization of cellular and molecular interactions and identification of novel therapeutic targets | |
Ellert-Miklaszewska et al. | 7aaRGD-a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas | |
Collins | Enhanced Co-Stimulatory Signaling Improves Car T Cell Effector Responses In Chronic Lymphocytic Leukemia | |
Harte | Chemokine and inhibitory receptor expression influences T cell migration and function in colorectal cancer patients | |
Kramářová | Deep profiling of immune regulatory networks in the bone marrow of patients with diverse acute myeloid leukemia subtypes | |
Tarhoni | Characterization of Biomarkers Associated with Response to Programmed Cell Death Protein-1/Programmed Cell Death Ligand-1 Inhibition in Patients with Advanced Stage Non-small Cell Lung Cancer | |
Spiliopoulou et al. | Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers | |
Palakurthi | Maximizing the Anti-tumor Potential of Immune Checkpoint Blockade through Modulation of Myeloid-specific CXCL16 and STAT1 Signaling | |
Aziz et al. | Study of immunomics and immune regulation in ovarian cancer | |
dos Santos | The role of hypoxia on immunomodulation at the colon cancer microenvironment |